ALVR AlloVir
- 0.782
- -0.015-1.82%
- 0.771
- -0.011-1.38%
AlloVir News
Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
Analysts' Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1
AlloVir Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)
Hold Rating on AlloVir Following Posoleucel Program Discontinuation and Strategic Shift
Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5
AlloVir Analyst Ratings
AlloVir's Positive Strides in T-Cell Therapy Development and Promising 3Q23 Financial Performance: A Buy Rating Analysis
Piper Sandler Keeps Their Buy Rating on AlloVir (ALVR)
B of A Securities Initiates Coverage On AlloVir With Buy Rating, Announces Price Target of $17
AlloVir Analyst Ratings
Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)
AlloVir Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AlloVir (ALVR), Cytokinetics (CYTK) and Guardant Health (GH)
SVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)
SVB Securities Sticks to Its Buy Rating for AlloVir (ALVR)
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Moderna (MRNA) and AlloVir (ALVR)
AlloVir (ALVR) Receives a Buy From Morgan Stanley
SVB Securities Adjusts Price Target on AlloVir to $19 From $16, Maintains Outperform Rating
Analysis
Price Target
No Data
